Haugabook SJ, Le T, Yager D, Zenk B, Healy BM, Eckman EA, Prada C, Younkin L, Murphy P, Pinnix I, Onstead L, Sambamurti K, Golde TE, Dickson D, Younkin SG, Eckman CB. Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin. FASEB J. 2001 Jan;15(1):16-18. Epub 2000 Nov 9 PubMed.

Comments

- Benjamin Wolozin
  Boston University School of Medicine
- Posted: 21 May 2002
Wortmannin is too toxic to be used as a therapeutic, but the idea of using such inhibitors is important to be aware of.

View all comments by Benjamin Wolozin

- John Hardy
  Institute of Neurology, UCL
- Posted: 30 Jun 2002
"An interesting paper which shows yet another way of reducing plaque load... as a result of the transgenic work, there are now many hopeful avenues for the drug industry and academics to look for Alzheimer treatments."

View all comments by John Hardy

Make a Comment

To make a comment you must login or register.

Paper

Tools

Comments

Make a Comment

This paper appears in the following:

News